Genotype-phenotype correlation in French patients with myelin protein zero gene-related inherited neuropathy.
CMT1B
Charcot-Marie-Tooth
clinical trial
hereditary peripheral neuropathy
myelin protein zero
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
23
04
2021
received:
16
02
2021
accepted:
19
05
2021
pubmed:
2
6
2021
medline:
21
10
2021
entrez:
1
6
2021
Statut:
ppublish
Résumé
Preparations for clinical trials of unfolded protein response (UPR) inhibitors (such as Sephin1) that target the upregulated UPR in patients with Charcot-Marie-Tooth disease (CMT) carrying MPZ mutations are currently underway. The inclusion criteria for these trials are still being formulated. Our objective was to characterize the relation between genotypes and phenotypes in patients with CMT caused by MPZ mutations, and to refine the inclusion criteria for future trials. Clinical and neurophysiological data of CMT patients with MPZ mutations were retrospectively collected at 11 French reference centers. Forty-four mutations in MPZ were identified in 91 patients from 61 families. There was considerable heterogeneity. The same mutation was found to cause either axonal or demyelinating neuropathy. Three groups were identified according to the age at disease onset. CMT Examination Score (CMTES) tended to be higher in the early (≤22 years) and adult (23-47 years) onset groups (mean CMTESv2 = 10.4 and 10.0, respectively) than in the late onset group (>47 years, mean CMTESv2 = 8.6, p = 0.47). There was a significant positive correlation between CMTESv2 and the age of patients in Groups I (p = 0.027) and II (p = 0.023), indicating that clinical severity progressed with age in these patients. To optimize the selection of CMT patients carrying MPZ mutations for the upcoming trials, inclusion criteria should take into account the pathophysiology of the disease (upregulated UPR). Recruited patients should have a mild to moderate disease severity and a disease onset at between 18 and 50 years, as these patients exhibit significant disease progression over time.
Sections du résumé
BACKGROUND AND PURPOSE
Preparations for clinical trials of unfolded protein response (UPR) inhibitors (such as Sephin1) that target the upregulated UPR in patients with Charcot-Marie-Tooth disease (CMT) carrying MPZ mutations are currently underway. The inclusion criteria for these trials are still being formulated. Our objective was to characterize the relation between genotypes and phenotypes in patients with CMT caused by MPZ mutations, and to refine the inclusion criteria for future trials.
METHODS
Clinical and neurophysiological data of CMT patients with MPZ mutations were retrospectively collected at 11 French reference centers.
RESULTS
Forty-four mutations in MPZ were identified in 91 patients from 61 families. There was considerable heterogeneity. The same mutation was found to cause either axonal or demyelinating neuropathy. Three groups were identified according to the age at disease onset. CMT Examination Score (CMTES) tended to be higher in the early (≤22 years) and adult (23-47 years) onset groups (mean CMTESv2 = 10.4 and 10.0, respectively) than in the late onset group (>47 years, mean CMTESv2 = 8.6, p = 0.47). There was a significant positive correlation between CMTESv2 and the age of patients in Groups I (p = 0.027) and II (p = 0.023), indicating that clinical severity progressed with age in these patients.
CONCLUSIONS
To optimize the selection of CMT patients carrying MPZ mutations for the upcoming trials, inclusion criteria should take into account the pathophysiology of the disease (upregulated UPR). Recruited patients should have a mild to moderate disease severity and a disease onset at between 18 and 50 years, as these patients exhibit significant disease progression over time.
Substances chimiques
Myelin P0 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2913-2921Informations de copyright
© 2021 European Academy of Neurology.
Références
Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet. 1974;6:98-118.
Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types i and ii. Brain. 1980;103(2):259-280.
Bird TD. Charcot-Marie-Tooth (CMT) Hereditary Neuropathy Overview 1. Clinical Characteristics of Charcot-Marie-Tooth (CMT) Hereditary Neuropathy. GeneReviews. 2020.
Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry; 2015;86:873-878.
Hayasaka K, Takada G, V.Ionasescu V. Mutation of the myelin Po gene in Charcot - Marie - Tooth neuropathy type 1B. Hum Mol Genet. 1993;2(9):1369-1372.
Bai Y, Wu X, Brennan KM, et al. Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B. Ann Clin Transl Neurol. 2018;5(4):445-455.
Warner LE, Hilz MJ, Appel SH, et al. Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth Type 1B, Dejerine-Sottas, and congenital Hypomyelination. Neuron. 1996;17(3):451-460.
Mandich P, Mancardi GL, Varese A, et al. Congenital hypomyelination due to myelin protein zero Q215X mutation. Ann Neurol. 1999;45(5):676-678.
Marrosu MG, Vaccargiu S, Marrosu G, Vannelli A, Cianchetti C, Muntoni F. Charcot-Marie-Tooth disease type 2 associated with mutation of the myelin protein zero gene. Neurology. 1998;50(5):1397-1401.
Chapon F, Latour P, Diraison P, Schaeffer S, Vandenberghe A. Axonal phenotype of Charcot-Marie-Tooth disease associated with a mutation in the myelin protein zero gene. J Neurol Neurosurg Psychiatry. 1999;66(6):779-782.
Das I, Krzyzosiak A, Schneider K, et al. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science (80-). 2015;348(6231):239-242.
Piscosquito G, Reilly MM, Schenone A, et al. Responsiveness of clinical outcome measures in Charcot−Marie−Tooth disease. Eur J Neurol. 2015;22(12):1556-1563.
Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2011;16(3):191-198.
Solari A, Laurà M, Salsano E, Radice D, Pareyson D. Reliability of clinical outcome measures in Charcot-Marie-Tooth disease. Neuromuscul Disord. 2008;18(1):19-26.
Lemmers RJLF, Van Der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science (80-). 2010;329(5999):1650-1653.
Sanmaneechai O, Feely S, Scherer SS, et al. Phenotype-genotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the myelin protein zero gene. J Peripher Nerv Syst. 2015;138:3180-3192.
Khajavi M, Inoue K, Wiszniewski W, Ohyama T, Snipes GJ, Lupski JR. Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. Am J Hum Genet. 2005;77(5):841-850.
Grandis M, Vigo T, Passalacqua M, et al. Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations. Hum Mol Genet. 2008;17(13):1877-1889.
Pennuto M, Tinelli E, Malaguti MC, et al. Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-Tooth 1B mice. Neuron. 2008;57(3):393-405.
Patzkó Á, Bai Y, Saporta MA, et al. Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice. Brain. 2012;135(12):3551-3566.
Planté-Bordeneuve V, Guiochon-Mantel A, Lacroix C, Lapresle J, Said G. The Roussy-Levy family: from the original description to the gene. Ann Neurol. 1999;46:770-773.
Hanemann CO, Gabreëls-Festen AAWM, De Jonghe P. Axon damage in CMT due to mutation in myelin protein P0. Neuromuscul Disord. 2001;11(8):753-756.
Baloh RH, Jen JC, Kim G, Baloh RW. Chronic cough due to Thr124Met mutation in the peripheral myelin protein zero (MPZ gene). Neurology. 2004;62(10):1905-1906.
Stojkovic T, De Seze J, Dubourg O, et al. Autonomic and respiratory dysfunction in Charcot-Marie-Tooth disease due to Thr124Met mutation in the myelin protein zero gene. Clin Neurophysiol. 2003;114(9):1609-1614.
Aboussouan LS, Lewis RA, Shy ME. Disorders of pulmonary function, sleep, and the upper airway in Charcot-Marie-Tooth disease. Lung. 2007;185(1):1-7.
Senderek J, Bergmann C, Stendel C, et al. Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. Am J Hum Genet. 2003;73(5):1106-1119.
Horacek O, Mazanec R, Morris CE, Kobesova A. Spinal deformities in hereditary motor and sensory neuropathy: a retrospective qualitative, quantitative, genotypical, and familial analysis of 175 patients. Spine (Phila Pa 1976). 2007;32(22):2502-2508.
Rajabally YA, Abbott RJ. Charcot-Marie-Tooth disease due to the Thr124Met mutation in the myelin protein zero gene associated with multiple sclerosis. J Peripher Nerv Syst. 2005;10(4):388-389.
Kilfoyle DH, Dyck PJ, Wu Y, et al. Myelin protein zero mutation His39Pro: hereditary motor and sensory neuropathy with variable onset, hearing loss, restless legs and multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(8):963-966.
Koros C, Evangelopoulos M-E, Kilidireas C, Andreadou E. Central nervous system demyelination in a Charcot-Marie-Tooth type 1A patient. Case Rep Neurol Med. 2013;2013:1-4.
Houlden H, Laura M, Wavrant-De Vrièze F, Blake J, Wood N, Reilly MM. Mutations in the HSP27 (HSPB1) gene cause dominant, recessive, and sporadic distal HMN/CMT type 2. Neurology. 2008;71(21):1660-1668.
Cassereau J, Casasnovas C, Gueguen N, et al. Simultaneous MFN2 and GDAP1 mutations cause major mitochondrial defects in a patient with CMT. Neurology. 2011;76(17):1524-1526.
Vital A, Latour P, Sole G, et al. A French family with Charcot-Marie-Tooth disease related to simultaneous heterozygous MFN2 and GDAP1 mutations. Neuromuscul Disord. 2012;22(8):735-741.
Tao F, Beecham GW, Rebelo AP, et al. Variation in SIPA1L2 is correlated with phenotype modification in Charcot- Marie- Tooth disease type 1A. Ann Neurol. 2019;85:316-330.